Agenda

Health Care is undergoing a revolution, driven by cutting-edge technology and innovative digital therapies that are reshaping treatment paradigms. Prescription Digital Therapeutics (PDTs) are not just a glimpse into the future—they are here, offering personalized treatment plans, enhanced adherence, and outcomes that rival traditional therapies. These groundbreaking interventions have the potential to transform care for millions of Americans, addressing a diverse range of conditions and illnesses.

AMCP members have a unique opportunity to be at the forefront of this revolution. By mastering the benefits, risks, and regulatory frameworks of PDTs, participants can play a pivotal role in assessing their clinical value, influencing coverage policies, and ensuring patients have affordable access to these next-generation therapies.

The newly updated AMCP Format for Formulary Submission 5.0 (AMCP Dossier) empowers members with the expertise to confidently evaluate PDTs for coverage. Through this dynamic workshop, participants will:

• Acquire actionable knowledge to navigate the complex landscape of PDTs.
• Develop practical skills to utilize AMCP resources effectively.
• Validate their expertise through a comprehensive Knowledge Assessment.

Why Join?

• Stay Ahead of the Curve: Gain exclusive insights into the latest advancements in healthcare technology.
• Enhance Your Professional Value: Earn a Certificate of Completion, demonstrating your proficiency and readiness to lead in the evolving field of PDTs.
• Drive Change in Healthcare: Equip yourself to shape coverage strategies that ensure equitable access to transformative therapies.

Don’t just observe the future of health care—become a key player in shaping it. Join this workshop and position yourself as a leader in integrating PDTs into health care coverage strategies.

Spaces are limited—reserve your spot today!

(D1) Charting a Better Path in Managing Multiple Myeloma: Overcoming Challenges and Driving Solutions
(L1) Legislative Impacts on Site of Service: What is the Big Deal?
(M1) Patient Engagement in Managed Care Pharmacy: Putting Policy into Practice
(R1) Unlocking the Value of Real-World Evidence (RWE): Insights for Payers and Manufacturers
(W1) The Legal Landscape of AI in Managed Care Pharmacy: Compliance, Ethics, and Future Trends

SpringWorks Therapeutics, in partnership with the Academy of Managed Care Pharmacy (AMCP), is hosting a free educational presentation on treatment advancements in neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) including a new FDA-approved treatment option for both adults and children with NF1-PN.

The event will take place on April 1, 2025, at 11:30 AM during the AMCP 2025 National Meeting, in the Blue Spotlight Theater within the Expo Hall at the George R. Brown Convention Center in Houston, TX. Lunch will be provided. 

Led by Dr. Timothy R. Gershon, MD, PhD, the presentation will cover the following: 

• NF1-PN: a rare, genetic, incurable, neuro-oncology disease
• Clinical manifestations and differential impact on adult and pediatric patients
• Unmet need and gaps in care
• Treatment management and treatment goals
• Clinical data for a new FDA-approved treatment option

This session is sponsored by SpringWorks Therapeutics.

Biogen is hosting a free educational presentation on the treatment of Friedreich ataxia. Join Dr. Michael Soileau, MD, FAAN, a Movement Disorder Neurologist from Texas Movement Disorder Specialists, as he discusses treating Friedreich ataxia. 

The event will be held on April 1st, 2025, at 11:45 AM, during the AMCP 2025 National Meeting. Join us in the [Yellow Spotlight Theater] within the Expo Hall at the George R. Brown Convention Center in Houston, TX. Lunch will be provided. 

This Spotlight Session is sponsored by Biogen.

This session will feature two esteemed formulary decision-makers, Dr. Lopes, M.D., M.S. and Dr. Cohen, MD, CPE, CHIE, as they explore the unique challenges associated with HIV. The discussion will cover the stigma surrounding HIV, the impact of social determinants of health (SDOH), and the objectives of the Ending the HIV Epidemic (EHE) initiative. Additionally, the program will provide an overview of the current state of HIV in the U.S. and examine key unmet needs in HIV treatment, including adherence challenges, privacy concerns, and delays in accessing appropriate therapies. The session will also highlight strategies to address these gaps and underscore the critical role of payers in advancing EHE goals.

Dr. Lopes currently serves as the Chief Medical Strategist at Geisinger Health System. Previously, she was the Chief Medical Officer at MagellanRx, a Pharmacy Benefit Management company overseeing medical, behavioral health, and pharmacy utilization for more than nine million members, where she served for seven years.

Dr. Cohen is the former Senior Vice President and Chief Medical Officer of Excellus Blue Cross Blue Shield. He also served as President of Lifetime Health Medical Group and Lifetime Care Home Health and Hospice subsidiaries.

This session is sponsored by Viiv Healthcare.

Patient communities are more than discussion forums- they are a powerful, lower-risk foundation for disease and product registries, offering life sciences organizations a direct path to real-world insights that drive both science and strategy. As a critical building block for prospective RWE initiatives, patient communities provide a space to test concepts, refine engagement strategies, and generate early evidence on treatment experiences.

This session will explore how online patient communities serve as a scalable, cost-effective starting point for RWE generation, delivering real-world insights that inform clinical trials, product launches, patient education campaigns, and payer negotiations. Through organic, qualitative discussions, companies can identify adherence barriers, side effect concerns, and treatment challenges across diverse populations—critical factors in payer engagement and formulary applications.

By harnessing Inspire’s unique access to real-world insights from millions of patients and caregivers, organizations can identify treatment patterns, detect emerging safety signals, and refine protocol designs with minimal complexity. Unlike traditional data sources, these insights are generated in real time, directly from patients and caregivers. As the need for deeper longitudinal data emerges, engaged participants can seamlessly transition into structured registries, ensuring continuity and efficiency in evidence generation.

Discover how patient communities can drive smarter decision-making, accelerate research, and optimize outcomes- all while fostering a more engaged and informed patient population.

This session is sponsored by Inspire.

Pharmacy costs are soaring, but health plans can do more with less. This session explores how automation and provider-driven interventions—like deprescribing, polypharmacy management, and biosimilar adoption—help optimize spending while improving member outcomes.

Learning Objective: 

• Learn effective strategies to communicate with and influence prescribers for cost-saving interventions.
• Discover how to improve member outcomes while optimizing drug spend and managing utilization.
• Understand how RazorMetrics achieves a 75% prescriber response rate by strategically engaging providers to reduce pharmacy costs.

This session is sponsored by RazorMetrics.

(D2) Advancing Equitable Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Management Strategies in Managed Care
(L2) Inflation Reduction Act Ripple Effects: Considerations for Patient Access and 340B
(M2) Employer Perspectives on High-Impact Drugs
{SP1) Unlocking the Basics of Value-Based Contracting: A Hands-On Introduction
(W2) Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: Perspectives and Challenges in Managed Care

In this 15-minute spotlight, discover how the strategic acquisition of Peregrine Market Access by Klick Health created a powerhouse in market access strategy, value communications, and commercialization. Learn how their combined expertise, shared culture of innovation, and deep scientific capabilities are redefining market access in the life sciences industry. This session will highlight the impact of collaboration in navigating payer landscapes, optimizing patient access, and driving success in an evolving healthcare market.

This session is sponsored by Klick Health.

Panel discussion of utilization management trends, real world evidence and Q4W dosing trends in biologic treatment of Atopic Dermatitis. 
Review of utilization management applications and treatment of Chronic Hand Eczema.

Speakers: 

• Diana Brixner, BPharm, PhD (Chair and Faculty) - University of Utah, Professor Emeritus
• Dana McCormick, PharmD (Faculty) - Senior Director, Pharmacy Advisory Services, Optum
• James Chambers, MSc, PhD (Faculty) - Professor, Tufts University

This session is sponsored by LEO Pharma.

Join Dr. Edward Eid,  Dermatologist and Researcher in the Department of Dermatology at Stanford University, and Sara Melton, EMBA, Executive Director of Market Access at Abeona Therapeutics, for an engaging pre-approval information exchange on prademagene zamikeracel (pz-cel), an investigational autologous cell-based gene therapy in development for Recessive Dystrophic Epidermolysis Bullosa (RDEB), an ultra-rare and serious genetic skin disorder.
 
The session will include a corporate overview, explore the burden of RDEB, introduce pz-cel and its investigational approach, and highlight key insights from the VIITAL Phase 3 study.

This session is sponsored by Abeona Therapeutics.

The speakers will discuss the rise in prevalence, severity, and irreversible vision threatening co-morbidities associated with myopia. We will explore the latest published data and discuss the primary causes of myopia, both genetic and environmental. We will also examine the significant health impact this epidemic has on patients and caregivers throughout their lives. Finally, the presentation will highlight an investigational prescription treatment for slowing myopic progression in pediatric patients.

Speakers:

• Patrick Johnson, PhD
  President, Sydnexis

• Gregory Ostrow, MD
  Pediatric Ophthalmologist, Scripps Clinic

This session is sponsored by Sydnexis.

(D3) [Spotlight 75] Transforming Cardiovascular Care: Using Collaborations to Improve Outcomes
(L3) Federal Legislative and Regulatory Update
(M3) Advancing Health Equity in Food Allergy Prevention and Treatment: Bridging Gaps in Care and Knowledge
(R3) Research Podium Session – Leveraging Real-Word Data to Advance Managed Care Pharmacy Practice
(W3) Collaborative Strategies for Pharmacist Reimbursement

Join the invite-only breakfast poster session at the AMCP 2025 conference, proudly sponsored by argenx. 

First approved in 2022 in generalized Myasthenia Gravis (gMG) and now in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), efgartigimod is first in its class for FcRn inhibition.
 
What to Expect:

• An exclusive tour of specially selected posters
• Network with the expert poster presenters
• Discuss the latest HEOR research in gMG and CIDP
• Enjoy a complimentary breakfast

Please RSVP to secure your spot on the entry list.

Join the invitation-only poster tour at AMCP 2025, proudly sponsored by Alnylam. 

This will be an opportunity to discuss the latest updates in the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM). Enjoy in-depth conversation with poster presenters highlighting their research, and network with managed care colleagues over a hot breakfast.  

Please RSVP to secure your spot on the entry list.

(L4) State Legislative and Regulatory Update
(M4) Future Horizons: Emerging Trends Impacting Managed Care Pharmacy
(R4) United in Care: A Modified Delphi Journey to Determine Meaningful Reporting Measures in Specialty Pharmacy
(W4)  Innovative Managed Care Solutions in Oncology: Enhancing Outcomes While Blunting the Cost Curve

In the past, PBM insourcing was seen as an immense challenge since it was complex, resource-intensive, and costly. Today, modern technologies make becoming your own PBM easier, allowing faster market entry with a pharmacy ecosystem that you define. In this session, RxSense Chief Pharmacy and Product Officer, Ramzi Yacoub, Pham.D., will explore the benefits of insourcing, focusing on how it can help you gain control, reduce costs and drive revenue.

This session is sponsored by RxSense.

This spotlight with address our current understanding disability accumulation, the considerations and limitation to managing disability accumulation, and discuss how smoldering- associated worsening expands the concept of progression independent of relapse activity in MS.

This session is sponsored by Sanofi.

In this session, we will explore the latest trends shaping the US payer landscape, with a focus on how payers are navigating access and formulary management within managed care organizations. Attendees will gain valuable insights from recent studies conducted by Cencora, featuring perspectives from decision-makers at health plans, pharmacy benefit managers, and integrated delivery networks.

Key topics will include:

·       Utilization of value access information in decision-making

·       Market access considerations for cell and gene therapies

·       Payer strategies regarding anti-obesity medications

·       Insights into payer perspectives on pre-approval information exchange.

By the end of the session, participants from biopharmaceutical manufacturers and managed care organizations will have a comprehensive understanding of the current payer landscape, along with insights into anticipated challenges and opportunities in access and formulary coverage.

This session is sponsored by Cencora.

(D6) Drug Pipeline: Traditional Pharmaceuticals (Brands and Generics)
(L6)Understanding 340B Stakeholder Perspectives, Litigation Trends, and Reform Prospects 
(W6)Understanding Complexities Specific to Gene Therapy and Navigating Available Management Strategies